About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.
Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma
>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting
Platinum-free interval should be >=6 months from the last dose of platinum-based chemotherapy
Upfront SCR not feasible
Non-epithelial or borderline tumors are excluded
Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.
Patients using more than one line of chemotherapy are excluded.
Patients who have platinum-resistant or refractory recurrence are excluded.